Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$321.86 USD

321.86
638,758

+0.07 (0.02%)

Updated Nov 7, 2024 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Arpita Dutt headshot

Pricing to Remain Pharma Headline Risk in 2017

by Arpita Dutt

Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.

    by Zacks Equity Research

      Arpita Dutt headshot

      Pharma Industry Outlook - February/March 2017

      by Arpita Dutt

      The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.

        Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates

        by Zacks Equity Research

        Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.

          The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda

          by Zacks Equity Research

          The Zacks Analyst Blog Highlights: Amgen, Procter & Gamble, Bank of America, Netflix and Honda

            Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

            by Zacks Equity Research

            Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

              Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.

              by Zacks Equity Research

              Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.

                Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

                by Zacks Equity Research

                Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

                  Amgen Looking to Broaden Leukemia Drug Blincyto's Label

                  by Zacks Equity Research

                  Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.

                    Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak

                    by Zacks Equity Research

                    Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.

                      Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

                      by Zacks Equity Research

                      Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

                        Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?

                        by Zacks Equity Research

                        Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release fourth-quarter 2016 results on Feb 9, before the opening bell.

                          Kinjel Shah headshot

                          Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat

                          by Kinjel Shah

                          Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.

                            Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.

                            by Zacks Equity Research

                            Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

                              Arpita Dutt headshot

                              Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

                              by Arpita Dutt

                              Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

                                Merck???s Keytruda Gets Priority Review for Bladder Cancer

                                by Zacks Equity Research

                                Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.

                                  Are Options Traders Betting on a Big Move in Amgen (AMGN) Stock?

                                  by Zacks Equity Research

                                  Investors in Amgen Inc. (AMGN) need to pay close attention to the stock based on moves in the options market lately.

                                    Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

                                    by Zacks Equity Research

                                    Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data

                                      by Arpita Dutt

                                      Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.

                                        Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?

                                        by Zacks Equity Research

                                        Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.

                                          The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

                                            Should You Sell Amgen (AMGN) Before Earnings?

                                            by Zacks Equity Research

                                            Amgen (AMGN) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

                                              Merck Keytruda Gets EU Approval for First-Line Lung Cancer

                                              by Zacks Equity Research

                                              Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

                                                Madeleine Johnson headshot

                                                Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

                                                by Madeleine Johnson

                                                Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

                                                  Kinjel Shah headshot

                                                  Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft

                                                  by Kinjel Shah

                                                  Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.